VIDEO: TAVR durability outperforms surgical valves

In a late-breaking long-term analysis presented at ACC 2022, the Medtronic CoreValve TAVR valve outperformed the surgical aortic valve replacement (SAVR) in terms of durability.

In a late-breaking long-term analysis presented at ACC.22, the Medtronic CoreValve TAVR valve outperformed surgical aortic valve replacement (SAVR) in terms of durability. 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

VIDEO: Lowering mortality rates from infected EP implantable cardiac devices

An implantable cardioverter defibrillator (ICD) and its associated leads viewed on a X-ray. Old leads are often abandon in veins and new ones added, but a new study of 1 million patients at ACC22 showed there is higher mortality if a device becomes infected and the leads are left behind. Image from RSNA.

An implantable cardioverter defibrillator (ICD) and its associated leads viewed on a X-ray. Old leads are often abandon in veins and new ones added, but a new study of 1 million patients at ACC22 showed there is higher mortality if a device becomes infected and the leads are left behind. Image from RSNA.

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.